Showing results (21-30 of 42) with videos related to

Sort By:
Pageof 5
The Journal of Biological Chemistry|October 7, 2003
Efficient targeting of conserved cryptic epitopes of infectious agents by single domain antibodies. African trypanosomes as paradigmBenoit Stijlemans, Katja Conrath, Virna Cortez-Retamozo, et al.
Nature Methods|October 25, 2006
Targeting and tracing antigens in live cells with fluorescent nanobodiesUlrich Rothbauer, Kourosh Zolghadr, Sergei Tillib, et al.
American Journal of Respiratory Cell and Molecular Biology|February 22, 2021
Novel Correctors and Potentiators Enhance Translational Readthrough in CFTR Nonsense MutationsVenkateshwar Mutyam, Jyoti Sharma, Yao Li, et al.
Archives of Biochemistry and Biophysics|May 16, 2012
A bacterial-two-hybrid selection system for one-step isolation of intracellularly functional NanobodiesMireille Pellis, Els Pardon, Kourosh Zolghadr, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|June 1, 2019
GLPG1837, a CFTR potentiator, in p.Gly551Asp (G551D)-CF patients: An open-label, single-arm, phase 2a study (SAPHIRA1)Jane C Davies, Olivier Van de Steen, Silke van Koningsbruggen-Rietschel, et al.
Protein Science : a Publication of the Protein Society|February 26, 2009
Camelid nanobodies raised against an integral membrane enzyme, nitric oxide reductaseKatja Conrath, Alice S Pereira, Carlos E Martins, et al.
Plos Pathogens|June 24, 2011
High affinity nanobodies against the Trypanosome brucei VSG are potent trypanolytic agents that block endocytosisBenoît Stijlemans, Guy Caljon, Senthil Kumar A Natesan, et al.
American Journal of Nephrology|April 29, 2025
GLPG2737, a CFTR Inhibitor, Prevents Cyst Growth in Preclinical Models of Autosomal Dominant Polycystic Kidney DiseaseVincent Dumont, Sandrine Meurisse, Katleen Verdonck, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|October 10, 2019
GLPG2737 in lumacaftor/ivacaftor-treated CF subjects homozygous for the F508del mutation: A randomized phase 2A trial (PELICAN)Silke van Koningsbruggen-Rietschel, Katja Conrath, Rainald Fischer, et al.
Frontiers in Pharmacology|May 31, 2019
Identification of GLPG/ABBV-2737, a Novel Class of Corrector, Which Exerts Functional Synergy With Other CFTR ModulatorsGert de Wilde, Maarten Gees, Sara Musch, et al.
Pageof 5